← Back

Guangzhou Wondfo Biotech Co Ltd

Guangzhou Wondfo Biotech Co.,Ltd, an in vitro diagnostics company, engages in the research and development, production, market, sale, and service of vitro diagnostic products in China and internationally. The company offers rapid test kits for COVID-19, drug of abuse, tumor marker, infectious disease, fertility, blood/serum/plasma test, and sexually transmitted diseases; immunofluorescence platform for detecting cardiac, thyroid, rheumatoid arthritis, sex hormone, anemia, gastroenterology, hypertension, thrombus, tumor, inflammation, diabetes, allergy, respiratory infection, kidney, brain injury, bone metabolism, and infectious disease, as well as Finecare FIA Meter X2, a 16-channel fluorescence immunoassay analyzing system; and chemiluminescence platform. It also provides semi-automatic blood coagulation analyzer and optical blood coagulation; blood gas biochemical analyzers and blood gas analyzers; molecular diagnostics platform; pathology straining system; and HbAlc analyzer. In addition, the company offers solutions, such as new-generation vitamin D, wondfo CRP campaign, international public health solutions, POCT lab, and COVID-19 total solution. Its products are used in clinical testing, critical illness, chronic disease management, primary care, epidemic monitoring, disaster relief, on-site law enforcement, and family personal health management. The company was founded in 1992 and is based in Guangzhou, China.

Price · split & dividend adjusted
News & notes moving 300482.CS
300482.CS▼6

Wondfo Biotech's 2026 interim net profit falls 35.24% to 123 million yuan

Wondfo Biotech released its 2026 interim report, with net profit attributable to the parent company at 123 million yuan, down 35.24% from the same period last year. Total operating revenue was 1.039 billion yuan, down 16.63% year-on-year. Net cash inflow from operating activities was 424 million yuan. The latest gross margin was 63.53%, ROE was 2.25%, and diluted earnings per share was 0.26 yuan. The company had 40,400 shareholders, and the top ten shareholders held 47.61% of the total share capital.
300482.CS ▼
Jiemian·3dRead more ▾
300482.CS▲

Wondfo Biotech obtains registration certificates for seven chemiluminescence medical devices

Wondfo Biotech announced that the company recently received seven chemiluminescence medical device registration certificates issued by the Guangdong Medical Products Administration, including a homocysteine assay kit, an insulin assay kit, glycated hemoglobin quality controls and calibrators, a laminin assay kit, a type III procollagen N-terminal peptide assay kit, and a type IV collagen assay kit. The newly approved products work in synergy with the company's existing offerings, continuously improving the product matrix for full-course liver disease testing, supplementing the need for islet function assessment, and supporting cardiovascular disease screening. The approval of these products has a positive impact on the company's development, but the impact on future revenue cannot yet be predicted.
300482.CS ▲
CLS·4dRead more ▾
300482.CS▲2

Wondfo Biotech's Controlling Shareholder Wang Jihua Completes Purchase of 1.156 Million Shares

Wondfo Biotech's controlling shareholder and actual controller Wang Jihua has purchased 1.156 million shares of the company through centralized competitive bidding on the Shenzhen Stock Exchange, representing approximately 0.25% of the company's total share capital. The purchase amount was approximately 20.0441 million yuan. This share purchase plan has now been fully implemented. A previous announcement indicated that Wang Jihua planned to purchase shares worth between 20 million yuan and 40 million yuan.
300482.CS ▲
北京商报·21dRead more ▾
300482.CS▲6

Wondfo Biotech Repurchases 1.74 Million Shares for a Total of 30.01 Million Yuan

Wondfo Biotech announced that as of July 31, 2026, the company had repurchased a cumulative 1.74 million shares through centralized competitive trading, representing 0.3708% of total share capital. The repurchase price ranged from 16.65 yuan to 17.5 yuan per share, with a total repurchase amount of 30.01 million yuan. In the first quarter of 2026, the company achieved revenue of 582 million yuan and net profit attributable to the parent of 84.4 million yuan.
300482.CS ▲
财中社·24dRead more ▾
300482.CS▲

BOE Technology's controlling shareholder plans 500 million to 1 billion yuan share increase; Hailiang's buyback price cap doubles current price

Several A-share listed companies have disclosed share increase or buyback plans by their controlling shareholders. BOE Technology's controlling shareholder, Beijing Electronics Holdings, plans to increase its holdings by 500 million to 1 billion yuan, with no price range set. Hailiang's controlling shareholder, Hailiang Group, plans to increase holdings by no less than 600 million yuan and no more than 1 billion yuan, with a maximum increase price of 35 yuan per share, roughly double the latest closing price of 16.79 yuan per share. Chongqing Port plans to buy back shares worth 20 million to 30 million yuan, at a price not exceeding 5.96 yuan per share, while its indirect controlling shareholder, Chongqing Logistics Group, simultaneously plans to increase holdings by 20 million to 30 million yuan. Wondfo Biotech's controlling shareholder, Wang Jihua, plans to increase holdings by 20 million to 40 million yuan, with no price range set. PRET Composites' controlling shareholder, Zhou Wen, has committed not to reduce his shareholding in the next 12 months.
000725.CS ▲002203.CS ▲300482.CS ▲600279.CG ▲002324.CS
证券时报·30dRead more ▾
300482.CS▲2

Wondfo Biotech's Controlling Shareholder Plans to Increase Stake by 20 Million to 40 Million Yuan

Wondfo Biotech announced that its controlling shareholder and actual controller, Wang Jihua, plans to increase her stake in the company through centralized bidding trading. The amount of the increase will be no less than 20 million yuan and no more than 40 million yuan, with no price range set for this increase.
300482.CS ▲
证券时报·30dRead more ▾
300482.CS▼

Wondfo Biotech Stock Hits New Low, Market Cap Down 70% from Peak, First Loss in a Decade Since Listing

Wondfo Biotech shares have fallen to a new low. As of the close on July 24, the stock ended at 15.69 yuan per share, after touching an intraday low of 15.66 yuan, a recent trough. The latest total market capitalization stands at 7.344 billion yuan, down 72 percent from its peak. The company's 2025 annual report shows revenue of 2.087 billion yuan, a year-on-year decline of 31.91 percent, and a net loss attributable to the parent of 63.02 million yuan, marking its first loss in the ten years since listing. The company attributed the sharp decline in performance mainly to deep industry adjustments, policies such as centralized procurement and DRG/DIP payment models suppressing demand and prices, as well as internal factors like adjustments to sales value-added tax rates, proactive divestiture of low-profit businesses, and strategic emerging businesses still in the investment phase. Despite the poor results, the company stated that new businesses such as tube-based chemiluminescence have made progress, its core competitiveness has not undergone any material adverse changes, and there is no significant risk to its ability to continue as a going concern.
300482.CS ▼
读创财经·33dRead more ▾
© 2026 MarketDXAsset